NFKB1 and acute respiratory distress syndrome: These findings indicated that raltegravir enhanced endothelial barrier integrity, thereby reducing ALI-associated inflammation via modulating HMGB1/TLR4/NF-κB signaling and inhibiting NLRP3 activation.